$459 Million is the total value of Opaleye Management Inc.'s 52 reported holdings in Q1 2024. The portfolio turnover from Q4 2023 to Q1 2024 was 34.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RYTM | Sell | RHYTHM PHARMACEUTICALS INC | $22,314,950 | -20.4% | 515,000 | -15.6% | 4.86% | -34.8% |
| CPRX | Sell | CATALYST PHARMACEUTICALS INC | $16,009,419 | -25.3% | 1,004,355 | -20.1% | 3.49% | -38.8% |
| EWTX | Sell | EDGEWISE THERAPEUTICS INC | $12,129,600 | +58.6% | 665,000 | -4.9% | 2.64% | +30.0% |
| Sell | ACELYRIN INC | $10,665,000 | -65.5% | 1,580,000 | -61.9% | 2.32% | -71.7% | |
| CRNX | Sell | CRINETICS PHARMACEUTICALS INC | $9,830,100 | -10.2% | 210,000 | -31.7% | 2.14% | -26.4% |
| ETON | Sell | ETON PHARMACEUTICALS INC | $9,171,679 | -17.2% | 2,445,781 | -3.3% | 2.00% | -32.2% |
| LQDA | Sell | LIQUIDIA CORPORATION | $5,826,250 | +8.8% | 395,000 | -11.2% | 1.27% | -10.8% |
| PCVX | Sell | VAXCYTE INC | $5,806,350 | +2.7% | 85,000 | -5.6% | 1.26% | -15.8% |
| Sell | NYXOAH S A | $4,316,800 | +169.8% | 320,000 | -7.2% | 0.94% | +121.4% | |
| URGN | Sell | UROGEN PHARMA LTD | $4,050,000 | -15.6% | 270,000 | -15.6% | 0.88% | -30.8% |
| RLMD | Sell | RELMADA THERAPEUTICS INC | $3,529,350 | -2.8% | 759,000 | -13.5% | 0.77% | -20.3% |
| GOSS | Sell | GOSSAMER BIO INC | $2,879,329 | +5.8% | 2,440,109 | -18.2% | 0.63% | -13.3% |
| PGEN | Sell | PRECIGEN INC | $1,373,875 | +1.3% | 947,500 | -6.4% | 0.30% | -17.2% |
| LRMR | Sell | LARIMAR THERAPEUTICS INC | $1,323,795 | -53.3% | 174,413 | -72.0% | 0.29% | -61.8% |
| MOR | Sell | MORPHOSYS AGsponsored ads | $1,179,100 | -17.9% | 65,000 | -55.2% | 0.26% | -32.7% |
| KNSA | Exit | KINIKSA PHARMACEUTICALS LTD | $0 | – | -37,500 | -100.0% | -0.17% | – |
| STRO | Exit | SUTRO BIOPHARMA INC | $0 | – | -301,491 | -100.0% | -0.34% | – |
| KALV | Exit | KALVISTA PHARMACEUTICALS INC | $0 | – | -150,000 | -100.0% | -0.49% | – |
| Exit | JASPER THERAPEUTICS INC | $0 | – | -3,985,340 | -100.0% | -0.84% | – | |
| Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -563,500 | -100.0% | -1.63% | – | |
| ARQT | Exit | ARCUTIS BIOTHERAPEUTICS INC | $0 | – | -1,960,000 | -100.0% | -1.68% | – |
| Exit | BIOHAVEN LTD | $0 | – | -200,000 | -100.0% | -2.28% | – | |
| IDYA | Exit | IDEAYA BIOSCIENCES INC | $0 | – | -311,500 | -100.0% | -2.95% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2024-05-29
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 42 | Q2 2024 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 30 | Q2 2024 | 3.6% |
| OCULAR THERAPEUTIX INC | 27 | Q2 2024 | 17.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| ETON PHARMACEUTICALS INC | 23 | Q2 2024 | 5.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| TG THERAPEUTICS INC | 20 | Q2 2024 | 10.1% |
| CRINETICS PHARMACEUTICALS INC | 20 | Q1 2024 | 5.6% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| iBio, Inc. | April 09, 2024 | 650,000 | 7.6% |
| OCULAR THERAPEUTIX, INC | February 14, 2024 | 6,070,000 | 5.5% |
| SANUWAVE Health, Inc. | February 14, 2024 | 115,493,554 | 9.1% |
| HARROW, INC. | February 09, 2024 | 3,820,000 | 10.9% |
| Jounce Therapeutics, Inc.Sold out | February 09, 2024 | 0 | 0.0% |
| Tracon Pharmaceuticals, Inc. | February 09, 2024 | 10 | 0.0% |
| Context Therapeutics Inc. | January 05, 2024 | 820,000 | 5.1% |
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-09-19 |
| SC 13G/A | 2024-09-18 |
| 3 | 2024-09-12 |
| 4 | 2024-09-12 |
| 4 | 2024-09-12 |
| SC 13G/A | 2024-09-12 |
| 4 | 2024-09-10 |
| N-PX | 2024-09-03 |
| 13F-HR | 2024-08-14 |
| 4 | 2024-07-18 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.